Chairman Resigns, Board Size Reduced to Three Directors

summarizeSummary

Kazia Therapeutics announced the resignation of Chairman Bryce Carmine and a reduction in its board size from four to three directors, effective March 31, 2026.

check_boxKey Events

• Chairman Resignation

  Bryce Carmine resigned as Chairman of the Board and from all committees, effective March 31, 2026. The company stated his resignation was not due to any disagreement.

• Board Size Reduction

  The Board of Directors was reduced from four to three members following Mr. Carmine's departure.

• Committee Appointment

  Ms. Ebru Davidson was appointed to the Audit, Risk and Governance Committee.

• Director Re-election

  Shareholders approved the re-election of Steven Coffey as a director at the Annual General Meeting.

auto_awesomeAnalysis

The departure of Chairman Bryce Carmine, even if amicable, represents a significant change in the company's leadership. The subsequent reduction of the Board of Directors from four to three members is a substantial governance change for a company of this size, potentially impacting oversight and strategic direction. Investors should monitor any future board appointments and further leadership changes.